| Bioactivity | DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR5 protein. DDO-2213 selectively inhibits MLL (mixed lineage leukemia) histone methyltransferase activity and the proliferation of MLL translocation-harboring cells. DDO-2213 can be used for MLL fusion leukemia research[1]. |
| Name | DDO-2213 |
| CAS | 2378768-36-4 |
| Formula | C24H27ClFN7O |
| Molar Mass | 483.97 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Chen W, et al. Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5-Mixed Lineage Leukemia 1 Protein-Protein Interaction for the Treatment of MLL Fusion Leukemia. J Med Chem. 2021 Jun 24;64(12):8221-8245. |
DDO-2213
CAS: 2378768-36-4 F: C24H27ClFN7O W: 483.97
DDO-2213 is an orally active and potent WDR5-MLL1 inhibitor, with an IC50 of 29 nM and a Kd value of 72.9 nM for the WDR
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.